• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

BORTEZOMIB Drug Record

  • Summary
  • Interactions
  • Claims
  • BORTEZOMIB chembl:CHEMBL325041 ApprovedAntineoplasticImmunotherapy

    Alternate Names:

    BORTEZOMIB HYDRATE
    VELCADE
    LDP-341
    BORTEZOMIB
    NSC-681239
    PS-341
    PS 341
    N-[(1R)-1-(DIHYDROXYBORYL)-3-METHYLBUTYL]-N-(PYRAZIN-2-YLCARBONYL)-L-PHENYLALANINAMIDE
    VELCADE®
    PEPTIDE BORONATE
    [(1R)-3-METHYL-1-({(2S)-3-PHENYL-2-[(PYRAZIN-2-YLCARBONYL)AMINO]PROPANOYL}AMINO)BUTYL]BORONIC ACID
    drugbank:00188
    rxcui:358258
    chembl:CHEMBL325041
    chemidplus:179324-69-7
    pubchem.compound:387447

    Drug Info:

    Year of Approval 2003
    Drug Class antineoplastic agents
    FDA Approval Multiple myeloma, Mantle cell lymphoma
    Drug Class Small molecule inhibitor
    FDA Approval approved
    Drug Class Small Molecule
    Drug Indications antineoplastic agent
    (14 More Sources)

    Publications:

    Kawamura S et al., 2014, Structurally novel highly potent proteasome inhibitors created by the structure-based hybridization of nonpeptidic belactosin derivatives and peptide boronates., J Med Chem
    Kumar et al., 2012, The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer., Cell
    Pearse et al., 2005, A neurotrophin axis in myeloma: TrkB and BDNF promote tumor-cell survival., Blood
    Chauhan et al., 2004, 2-Methoxyestardiol and bortezomib/proteasome-inhibitor overcome dexamethasone-resistance in multiple myeloma cells by modulating Heat Shock Protein-27., Apoptosis
    Blackburn C et al., 2010, Optimization of a series of dipeptides with a P3 threonine residue as non-covalent inhibitors of the chymotrypsin-like activity of the human 20S proteasome., Bioorg Med Chem Lett
    Fernández et al., 2005, Differential regulation of noxa in normal melanocytes and melanoma cells by proteasome inhibition: therapeutic implications., Cancer Res.
    Kawamura S et al., 2013, Potent proteasome inhibitors derived from the unnatural cis-cyclopropane isomer of Belactosin A: synthesis, biological activity, and mode of action., J Med Chem
    Pikman et al., 2017, Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia., Clin. Cancer Res.
    Duechler et al., 2005, In vitro cytotoxic effect of proteasome inhibitor bortezomib in combination with purine nucleoside analogues on chronic lymphocytic leukaemia cells., Eur. J. Haematol.
    Meißner T et al., 2017, Metastatic triple-negative breast cancer patient with <i>TP53</i> tumor mutation experienced 11 months progression-free survival on bortezomib monotherapy without adverse events after ending standard treatments with grade 3 adverse events., Cold Spring Harb Mol Case Stud
    Shringarpure et al., 2006, Gene expression analysis of B-lymphoma cells resistant and sensitive to bortezomib., Br. J. Haematol.
    Bodoor et al., 2010, FGFR3 mutational status and protein expression in patients with bladder cancer in a Jordanian population., Cancer Epidemiol
    Chang et al., 2016, Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity., Nat. Biotechnol.
    Guan et al., 2009, Bortezomib therapeutic effect is associated with expression of FGFR3 in multiple myeloma cells., Anticancer Res.
    Otsuka et al., 2011, Constitutively active FGFR3 with Lys650Glu mutation enhances bortezomib sensitivity in plasma cell malignancy., Anticancer Res.
    Chell et al., 2013, Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance., Oncogene
    MacConaill et al., 2014, Prospective enterprise-level molecular genotyping of a cohort of cancer patients., J Mol Diagn
    Qing et al., 2009, Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice., J. Clin. Invest.
    Favis R et al., 2011, Genetic variation associated with bortezomib-induced peripheral neuropathy., Pharmacogenet Genomics
    Nawrocki et al., 2005, Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells., Cancer Res.
    Janku et al., 2011, PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors., Mol. Cancer Ther.
    Jung et al., 2001, Flavopiridol increases sensitization to gemcitabine in human gastrointestinal cancer cell lines and correlates with down-regulation of ribonucleotide reductase M2 subunit., Clin. Cancer Res.
    Ngo BT et al., 2010, Monitoring bortezomib therapy in multiple myeloma: screening of cyclin D1, D2, and D3 via reliable real-time polymerase chain reaction and association with clinico-pathological features and outcome., Leuk Lymphoma
  • BORTEZOMIB   CAPN1

    Interaction Score: 1.37

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20875739


    Sources:
    DTC

  • BORTEZOMIB   PMAIP1

    Interaction Score: 1.37

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16024631


    Sources:
    NCI

  • BORTEZOMIB   PSMD1

    Interaction Score: 1.03

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction 26S proteosome inhibitor
    Direct Interaction yes
    Trial Name Velcade

    PMIDs:
    24524217


    Sources:
    DTC MyCancerGenome TdgClinicalTrial ChemblInteractions TEND

  • BORTEZOMIB   PSMD2

    Interaction Score: 1.03

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction 26S proteosome inhibitor
    Trial Name Velcade

    PMIDs:
    24524217


    Sources:
    DTC MyCancerGenome TdgClinicalTrial ChemblInteractions TEND

  • BORTEZOMIB   CTSL

    Interaction Score: 0.69

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20875739


    Sources:
    DTC

  • BORTEZOMIB   F12

    Interaction Score: 0.69

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20875739


    Sources:
    DTC

  • BORTEZOMIB   PSMC4

    Interaction Score: 0.69

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction 26S proteosome inhibitor
    Direct Interaction yes

    PMIDs:
    24524217


    Sources:
    DTC MyCancerGenome ChemblInteractions

  • BORTEZOMIB   PSMD7

    Interaction Score: 0.69

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction 26S proteosome inhibitor
    Direct Interaction yes

    PMIDs:
    24524217


    Sources:
    DTC MyCancerGenome ChemblInteractions

  • BORTEZOMIB   PSMC3

    Interaction Score: 0.69

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction 26S proteosome inhibitor
    Direct Interaction yes

    PMIDs:
    24524217


    Sources:
    DTC MyCancerGenome ChemblInteractions

  • BORTEZOMIB   PSMC6

    Interaction Score: 0.69

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction 26S proteosome inhibitor
    Direct Interaction yes

    PMIDs:
    24524217


    Sources:
    DTC MyCancerGenome ChemblInteractions

  • BORTEZOMIB   PSMD12

    Interaction Score: 0.69

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction 26S proteosome inhibitor
    Direct Interaction yes

    PMIDs:
    24524217


    Sources:
    DTC MyCancerGenome ChemblInteractions

  • BORTEZOMIB   PSMD6

    Interaction Score: 0.69

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction 26S proteosome inhibitor
    Direct Interaction yes

    PMIDs:
    24524217


    Sources:
    DTC MyCancerGenome ChemblInteractions

  • BORTEZOMIB   PSMC1

    Interaction Score: 0.69

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction 26S proteosome inhibitor
    Direct Interaction yes

    PMIDs:
    24524217


    Sources:
    DTC MyCancerGenome ChemblInteractions

  • BORTEZOMIB   PSMD13

    Interaction Score: 0.69

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction 26S proteosome inhibitor

    PMIDs:
    24524217


    Sources:
    DTC MyCancerGenome ChemblInteractions

  • BORTEZOMIB   PSMD8

    Interaction Score: 0.69

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction 26S proteosome inhibitor
    Direct Interaction yes

    PMIDs:
    24524217


    Sources:
    DTC MyCancerGenome ChemblInteractions

  • BORTEZOMIB   PSMD3

    Interaction Score: 0.69

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction 26S proteosome inhibitor
    Direct Interaction yes

    PMIDs:
    24524217


    Sources:
    DTC MyCancerGenome ChemblInteractions

  • BORTEZOMIB   PSMB1

    Interaction Score: 0.69

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Novel drug target Established target
    Trial Name Velcade
    Direct Interaction yes

    PMIDs:
    24524217


    Sources:
    DTC MyCancerGenome TdgClinicalTrial ChemblInteractions TEND

  • BORTEZOMIB   PSMD11

    Interaction Score: 0.69

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction 26S proteosome inhibitor
    Direct Interaction yes

    PMIDs:
    24524217


    Sources:
    DTC MyCancerGenome ChemblInteractions

  • BORTEZOMIB   PSMC2

    Interaction Score: 0.69

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction 26S proteosome inhibitor
    Direct Interaction yes

    PMIDs:
    24524217


    Sources:
    DTC MyCancerGenome ChemblInteractions

  • BORTEZOMIB   PSMB2

    Interaction Score: 0.59

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction 26S proteosome inhibitor
    Direct Interaction yes
    Trial Name Velcade

    PMIDs:
    24524217


    Sources:
    DTC MyCancerGenome TdgClinicalTrial ChemblInteractions TEND

  • BORTEZOMIB   PSMB9

    Interaction Score: 0.55

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction 26S proteosome inhibitor
    Direct Interaction yes

    PMIDs:
    24524217


    Sources:
    DTC MyCancerGenome ChemblInteractions

  • BORTEZOMIB   PSMB4

    Interaction Score: 0.55

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction 26S proteosome inhibitor
    Direct Interaction yes

    PMIDs:
    24524217


    Sources:
    DTC MyCancerGenome ChemblInteractions

  • BORTEZOMIB   PSMB7

    Interaction Score: 0.55

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction 26S proteosome inhibitor
    Direct Interaction yes

    PMIDs:
    24524217


    Sources:
    DTC MyCancerGenome ChemblInteractions

  • BORTEZOMIB   PSMB6

    Interaction Score: 0.55

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction 26S proteosome inhibitor
    Direct Interaction yes

    PMIDs:
    24524217


    Sources:
    DTC MyCancerGenome ChemblInteractions

  • BORTEZOMIB   PSMC5

    Interaction Score: 0.55

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction 26S proteosome inhibitor
    Direct Interaction yes

    PMIDs:
    24524217


    Sources:
    DTC MyCancerGenome ChemblInteractions

  • BORTEZOMIB   PSMA6

    Interaction Score: 0.55

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction 26S proteosome inhibitor
    Direct Interaction yes

    PMIDs:
    24524217


    Sources:
    DTC MyCancerGenome ChemblInteractions

  • BORTEZOMIB   PSMA2

    Interaction Score: 0.55

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction 26S proteosome inhibitor
    Direct Interaction yes

    PMIDs:
    24524217


    Sources:
    DTC MyCancerGenome ChemblInteractions

  • BORTEZOMIB   PSMD4

    Interaction Score: 0.55

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction 26S proteosome inhibitor

    PMIDs:
    24524217


    Sources:
    DTC MyCancerGenome ChemblInteractions

  • BORTEZOMIB   PSMA1

    Interaction Score: 0.55

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction 26S proteosome inhibitor
    Direct Interaction yes

    PMIDs:
    24524217


    Sources:
    DTC MyCancerGenome ChemblInteractions

  • BORTEZOMIB   PSMA3

    Interaction Score: 0.55

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction 26S proteosome inhibitor
    Direct Interaction yes

    PMIDs:
    24524217


    Sources:
    DTC MyCancerGenome ChemblInteractions

  • BORTEZOMIB   PSMA5

    Interaction Score: 0.55

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction 26S proteosome inhibitor
    Direct Interaction yes

    PMIDs:
    24524217


    Sources:
    DTC MyCancerGenome ChemblInteractions

  • BORTEZOMIB   PSMB10

    Interaction Score: 0.55

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction 26S proteosome inhibitor
    Direct Interaction yes

    PMIDs:
    24524217


    Sources:
    DTC MyCancerGenome ChemblInteractions

  • BORTEZOMIB   PSMA8

    Interaction Score: 0.55

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction 26S proteosome inhibitor
    Direct Interaction yes

    PMIDs:
    24524217


    Sources:
    DTC MyCancerGenome ChemblInteractions

  • BORTEZOMIB   PSMA7

    Interaction Score: 0.55

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction 26S proteosome inhibitor
    Direct Interaction yes

    PMIDs:
    24524217


    Sources:
    DTC MyCancerGenome ChemblInteractions

  • BORTEZOMIB   PSMB3

    Interaction Score: 0.55

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction 26S proteosome inhibitor
    Direct Interaction yes

    PMIDs:
    24524217


    Sources:
    DTC MyCancerGenome ChemblInteractions

  • BORTEZOMIB   PSMB5

    Interaction Score: 0.53

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Novel drug target Established target
    Trial Name Velcade
    Mechanism of Interaction 26S proteosome inhibitor

    PMIDs:
    24524217 23547757


    Sources:
    DTC MyCancerGenome TdgClinicalTrial ChemblInteractions TEND

  • BORTEZOMIB   SEM1

    Interaction Score: 0.52

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction 26S proteosome inhibitor
    Direct Interaction yes

    PMIDs:
    24524217


    Sources:
    DTC ChemblInteractions

  • BORTEZOMIB   ADRM1

    Interaction Score: 0.52

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction 26S proteosome inhibitor
    Direct Interaction yes

    PMIDs:
    24524217


    Sources:
    DTC ChemblInteractions

  • BORTEZOMIB   GATA2

    Interaction Score: 0.52

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy bortezomib + fasudil
    Indication/Tumor Type non-small cell lung carcinoma
    Response Type sensitive

    PMIDs:
    22541434


    Sources:
    JAX-CKB CIViC

  • BORTEZOMIB   PRSS3

    Interaction Score: 0.46

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20875739


    Sources:
    DTC

  • BORTEZOMIB   PRSS2

    Interaction Score: 0.46

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20875739


    Sources:
    DTC

  • BORTEZOMIB   CTSB

    Interaction Score: 0.46

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20875739


    Sources:
    DTC

  • BORTEZOMIB   PSMA4

    Interaction Score: 0.46

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction 26S proteosome inhibitor
    Direct Interaction yes

    PMIDs:
    24524217


    Sources:
    DTC MyCancerGenome ChemblInteractions

  • BORTEZOMIB   PSMB11

    Interaction Score: 0.41

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction 26S proteosome inhibitor
    Direct Interaction yes

    PMIDs:
    24524217


    Sources:
    DTC ChemblInteractions

  • BORTEZOMIB   PRSS1

    Interaction Score: 0.41

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20875739


    Sources:
    DTC TTD

  • BORTEZOMIB   PSMB8

    Interaction Score: 0.39

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction 26S proteosome inhibitor

    PMIDs:
    24524217


    Sources:
    DTC MyCancerGenome ChemblInteractions

  • BORTEZOMIB   PSMD10P1

    Interaction Score: 0.34

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    None found


    Sources:
    MyCancerGenome

  • BORTEZOMIB   PIPSL

    Interaction Score: 0.34

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    None found


    Sources:
    MyCancerGenome

  • BORTEZOMIB   PSMF1

    Interaction Score: 0.34

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    None found


    Sources:
    MyCancerGenome

  • BORTEZOMIB   PSME4

    Interaction Score: 0.34

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    None found


    Sources:
    MyCancerGenome

  • BORTEZOMIB   BCL2L2

    Interaction Score: 0.34

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15813915


    Sources:
    NCI

  • BORTEZOMIB   PSME2

    Interaction Score: 0.34

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    None found


    Sources:
    MyCancerGenome

  • BORTEZOMIB   PSMD5

    Interaction Score: 0.34

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    None found


    Sources:
    MyCancerGenome

  • BORTEZOMIB   PSMD10

    Interaction Score: 0.34

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    None found


    Sources:
    MyCancerGenome

  • BORTEZOMIB   PSME1

    Interaction Score: 0.34

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    None found


    Sources:
    MyCancerGenome

  • BORTEZOMIB   PSME2P2

    Interaction Score: 0.34

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    None found


    Sources:
    MyCancerGenome

  • BORTEZOMIB   PSMD10P3

    Interaction Score: 0.34

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    None found


    Sources:
    MyCancerGenome

  • BORTEZOMIB   PSMD9

    Interaction Score: 0.34

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    None found


    Sources:
    MyCancerGenome

  • BORTEZOMIB   PSME3

    Interaction Score: 0.34

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    None found


    Sources:
    MyCancerGenome

  • BORTEZOMIB   PSMD10P2

    Interaction Score: 0.34

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    None found


    Sources:
    MyCancerGenome

  • BORTEZOMIB   PSMC1P1

    Interaction Score: 0.34

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    None found


    Sources:
    MyCancerGenome

  • BORTEZOMIB   PSMC3IP

    Interaction Score: 0.34

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    None found


    Sources:
    MyCancerGenome

  • BORTEZOMIB   PSMD4P1

    Interaction Score: 0.34

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    None found


    Sources:
    MyCancerGenome

  • BORTEZOMIB   PSMD14

    Interaction Score: 0.25

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction 26S proteosome inhibitor
    Direct Interaction yes

    PMIDs:
    24524217


    Sources:
    DTC MyCancerGenome ChemblInteractions

  • BORTEZOMIB   KLK4

    Interaction Score: 0.23

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • BORTEZOMIB   PLAT

    Interaction Score: 0.17

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20875739


    Sources:
    DTC

  • BORTEZOMIB   HSPB2

    Interaction Score: 0.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15004512


    Sources:
    NCI

  • BORTEZOMIB   PRB2

    Interaction Score: 0.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • BORTEZOMIB   FGFR3

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Clinical Status preclinical
    Pathway activation
    Variant Effect gain-of-function

    PMIDs:
    20542753 26619011 19331127 21273588 22869148 25157968 19381019


    Sources:
    DoCM

  • BORTEZOMIB   E2F1

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11489836


    Sources:
    NCI

  • BORTEZOMIB   NOTCH1

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Evidence Type Actionable
    Approval Status Preclinical - Cell culture
    Response Type sensitive

    PMIDs:
    28151717


    Sources:
    JAX-CKB

  • BORTEZOMIB   CTLA4

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21228734


    Sources:
    PharmGKB

  • BORTEZOMIB   CCND1

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20578819


    Sources:
    CIViC

  • BORTEZOMIB   XIAP

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15813915


    Sources:
    NCI

  • BORTEZOMIB   RB1

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Ribociclib + Bortezomib
    Indication/Tumor Type T-cell adult acute lymphocytic leukemia
    Response Type sensitive

    PMIDs:
    28151717


    Sources:
    JAX-CKB

  • BORTEZOMIB   DDIT3

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16357160


    Sources:
    NCI

  • BORTEZOMIB   F2

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20875739


    Sources:
    DTC

  • BORTEZOMIB   PLG

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20875739


    Sources:
    DTC

  • BORTEZOMIB   HSPA4

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16846475


    Sources:
    NCI

  • BORTEZOMIB   NFKB2

    Interaction Score: 0.03

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Notes

    PMIDs:
    None found


    Sources:
    TALC TTD

  • BORTEZOMIB   BDNF

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15657181


    Sources:
    NCI

  • BORTEZOMIB   BCL2

    Interaction Score: 0.02

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Notes

    PMIDs:
    None found


    Sources:
    TALC

  • BORTEZOMIB   BAX

    Interaction Score: 0.01

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Notes

    PMIDs:
    None found


    Sources:
    TALC

  • BORTEZOMIB   KRAS

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Evidence Type Actionable
    Approval Status Preclinical
    Response Type sensitive

    PMIDs:
    22541434


    Sources:
    JAX-CKB

  • BORTEZOMIB   PIK3CA

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Bortezomib + Temsirolimus + Topotecan
    Indication/Tumor Type small intestine adenocarcinoma
    Response Type resistant

    PMIDs:
    21216929


    Sources:
    JAX-CKB

  • BORTEZOMIB   FLT3

    Interaction Score: 0.01

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    None found


    Sources:
    MyCancerGenomeClinicalTrial

  • BORTEZOMIB   NFKB1

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    ClearityFoundationClinicalTrial

  • BORTEZOMIB   TP53

    Interaction Score: 0.01

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Notes

    PMIDs:
    28679691


    Sources:
    TALC CIViC

  • BORTEZOMIB   NFE2L2

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • BORTEZOMIB   AR

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • TEND: BORTEZOMIB

    • Version: 01-August-2011

    Alternate Names:
    BORTEZOMIB Primary Drug Name

    Drug Info:
    Drug Class antineoplastic agents
    Year of Approval 2003

    Publications:

  • MyCancerGenome: BORTEZOMIB

    • Version: 20-Jun-2017

    Alternate Names:
    LDP341 Development Name
    MLN341 Development Name
    PS-341 Development Name

    Drug Info:
    Drug Class Small molecule inhibitor
    FDA Approval Multiple myeloma, Mantle cell lymphoma

    Publications:

  • TdgClinicalTrial: BORTEZOMIB

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antineoplastic agent
    Drug Class Small Molecule
    FDA Approval approved

    Publications:

  • DTC: BORTEZOMIB

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL325041 ChEMBL Drug ID

    Drug Info:

    Publications:
    Kawamura S et al., 2014, Structurally novel highly potent proteasome inhibitors created by the structure-based hybridization of nonpeptidic belactosin derivatives and peptide boronates., J Med Chem
    Blackburn C et al., 2010, Optimization of a series of dipeptides with a P3 threonine residue as non-covalent inhibitors of the chymotrypsin-like activity of the human 20S proteasome., Bioorg Med Chem Lett
    Kawamura S et al., 2013, Potent proteasome inhibitors derived from the unnatural cis-cyclopropane isomer of Belactosin A: synthesis, biological activity, and mode of action., J Med Chem

  • NCI: PS-341

    • Version: 14-September-2017

    Alternate Names:
    C1851 NCI drug code

    Drug Info:

    Publications:
    Jung et al., 2001, Flavopiridol increases sensitization to gemcitabine in human gastrointestinal cancer cell lines and correlates with down-regulation of ribonucleotide reductase M2 subunit., Clin. Cancer Res.
    Chauhan et al., 2004, 2-Methoxyestardiol and bortezomib/proteasome-inhibitor overcome dexamethasone-resistance in multiple myeloma cells by modulating Heat Shock Protein-27., Apoptosis

  • NCI: BORTEZOMIB

    • Version: 14-September-2017

    Alternate Names:
    C1851 NCI drug code

    Drug Info:

    Publications:
    Duechler et al., 2005, In vitro cytotoxic effect of proteasome inhibitor bortezomib in combination with purine nucleoside analogues on chronic lymphocytic leukaemia cells., Eur. J. Haematol.
    Nawrocki et al., 2005, Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells., Cancer Res.
    Pearse et al., 2005, A neurotrophin axis in myeloma: TrkB and BDNF promote tumor-cell survival., Blood

  • JAX-CKB: Bortezomib

    • Version: 27-September-2017

    Alternate Names:

    Drug Info:

    Publications:
    Janku et al., 2011, PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors., Mol. Cancer Ther.
    Pikman et al., 2017, Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia., Clin. Cancer Res.

  • JAX-CKB: bortezomib

    • Version: 27-September-2017

    Alternate Names:

    Drug Info:

    Publications:
    Kumar et al., 2012, The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer., Cell

  • DoCM: BORTEZOMIB

    • Version: 27-September-2017

    Alternate Names:

    Drug Info:

    Publications:
    Chang et al., 2016, Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity., Nat. Biotechnol.
    Guan et al., 2009, Bortezomib therapeutic effect is associated with expression of FGFR3 in multiple myeloma cells., Anticancer Res.
    Bodoor et al., 2010, FGFR3 mutational status and protein expression in patients with bladder cancer in a Jordanian population., Cancer Epidemiol

  • PharmGKB: bortezomib

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Favis R et al., 2011, Genetic variation associated with bortezomib-induced peripheral neuropathy., Pharmacogenet Genomics

  • CIViC: BORTEZOMIB

    • Version: 14-September-2020

    Alternate Names:

    Drug Info:

    Publications:
    Kumar et al., 2012, The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer., Cell
    Meißner T et al., 2017, Metastatic triple-negative breast cancer patient with <i>TP53</i> tumor mutation experienced 11 months progression-free survival on bortezomib monotherapy without adverse events after ending standard treatments with grade 3 adverse events., Cold Spring Harb Mol Case Stud
    Ngo BT et al., 2010, Monitoring bortezomib therapy in multiple myeloma: screening of cyclin D1, D2, and D3 via reliable real-time polymerase chain reaction and association with clinico-pathological features and outcome., Leuk Lymphoma

  • TTD: PS-341

    • Version: 2020.06.01

    Alternate Names:
    D03AJX TTD Drug ID

    Drug Info:

    Publications:

  • TALC: BORTEZOMIB

    • Version: 12-May-2016

    Alternate Names:
    BORTEZOMIB Primary Drug Name
    BORTEZOMIB Drug Generic Name
    VELCADE Drug Trade Name

    Drug Info:

    Publications:

  • TTD: Bortezomib

    • Version: 2020.06.01

    Alternate Names:
    D0SH3I TTD Drug ID

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL325041

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL325041

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • MyCancerGenomeClinicalTrial: BORTEZOMIB

    • Version: 30-February-2014

    Alternate Names:

    Drug Info:

    Publications:

  • ClearityFoundationClinicalTrial: BORTEZOMIB

    • Version: 15-June-2013

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21